The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Open accessAbstract
mRNA vaccines are rapidly emerging as a powerful platform for infectious diseases because they are well tolerated, immunogenic, and scalable and are built on precise but adaptable antigen design. We show that two immunizations of modified non-replicating mRNA encoding influenza H10 hemagglutinin (HA) and encapsulated in lipid nanoparticles (LNP) induce protective HA inhibition titers and H10-specific CD4 + T cell responses after intramuscular or intradermal delivery in rhesus macaques. Administration of LNP/mRNA induced rapid and local infiltration of neutrophils, monocytes, and dendritic cells (DCs) to the site of administration and the draining lymph nodes (LNs). While these cells efficiently internalized LNP, mainly monocytes and DCs translated the mRNA and upregulated key co-stimulatory receptors (CD80 and CD86). This coincided with upregulation of type I IFN-inducible genes, including MX1 and CXCL10. The innate immune activation was transient and resulted in priming of H10-specific CD4 + T cells exclusively in the vaccine-draining LNs. Collectively, this demonstrates that mRNA-based vaccines induce type-I IFN-polarized innate immunity and, when combined with antigen production by antigen-presenting cells, lead to generation of potent vaccine-specific responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More robust germinal centre responses are consistent with antigen dissemination to multiple lymph nodes and the self-adjuvating characteristics of the mRNA–lipid nanoparticle vaccine platform compared to nonadjuvanted inactivated vaccines used for seasonal influenza virus vaccination7,20,21.”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [21]
In the citing paper
“and enhances delivery to the cytosol of antigen-presenting cells (Liang et al., 2017, Lindsay et al., 2019).”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Liang et al., 2017
In the citing paper
“Vaccine targeted cell types (see Mode of action), such as dendritic cells (DCs) and monocytes, highly express LDL receptors and other scavenger receptors [41]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [41]
In the citing paper
“Similar to the more classical vaccine approaches, the COVID-19 mRNA vaccines are injected in the muscle, where they trigger localized and transient inflammation that recruits different immune cells to the injection site (Fig. 3 ) [11,41]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [41]
In the citing paper
“According to mechanistic studies on the fate of mRNA LNPs in rhesus monkeys, primarily monocytes and DC subsets translate the mRNA, likely involving ApoE dependent endocytosis [41]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [41]
In the citing paper
“In addition, they could detect mature, mRNA-transfected APCs in the draining LNs.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“Although all of these cell types were able to internalize mRNA LNPs, only monocytes and myeloid DCs showed high translation of the mRNA.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“With respect to the resulting immune response, they showed that i.d.delivery resulted in an earlier activation of skin DCs and a more efficient migration to draining LNs, as well as a prolonged antigen availability at the injection site.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“For both administration routes, they could show a rapid recruitment of neutrophils, monocytes and different DC subsets to the injection site (skin or muscle).”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
In the citing paper
“Together, this resulted in a superior immunogenicity compared to i.m. delivery, as i.d.injection resulted in the highest antibody titers and CD4 + T cell activation.”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,927
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Skin immune sentinels in health and disease
Nestle, F. O., Meglio, P. D., Qin, J., & Nickoloff, B. J. (2009) · Nature reviews. Immunology · doi:10.1038/nri2622 · Cited by 1,529
Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
Cros, J. F., Cagnard, N., Woollard, K. J., Patey, N., Zhang, S., Sénéchal, B., Puel, A., Biswas, S. K., Moshous, D., Pïcard, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.012 · Cited by 1,320
Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C. J., Dunbar, P. R., Wadley, R. B., Jeet, V., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092140 · Cited by 1,019
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 384
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates
Buckley, M., Araínga, M., Maiorino, L., Pires, I. S., Kim, B., Michaels, K. K., Dye, J., Qureshi, K., Zhang, Y. J., Mak, H. H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.008 · Cited by 59
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines
Tregoning, J. S., Stirling, D. C., Wang, Z., Flight, K. E., Brown, J. C., Blakney, A. K., McKay, P. F., Cunliffe, R. F., Murugaiah, V., Fox, C. B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.024 · Cited by 57
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 59
New Technologies for Influenza Vaccines
Rockman, S. P., Laurie, K., Parkes, S., Wheatley, A. K., & Barr, I. (2020) · Microorganisms · doi:10.3390/microorganisms8111745 · Cited by 58
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Mochida, Y., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.022 · Cited by 56
Willis, E., Pardi, N., Parkhouse, K., Mui, B. L., Tam, Y. K., Weissman, D., & Hensley, S. E. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5701 · Cited by 54
Takano, T., Morikawa, M., Adachi, Y., Kabasawa, K., Sax, N., Moriyama, S., Sun, L., Isogawa, M., Nishiyama, A., Onodera, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100631 · Cited by 55
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Tian, Y. P., Tirrell, M., & LaBelle, J. L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102600 · Cited by 53
Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination
Cognetti, J. S., & Miller, B. L. (2021) · Sensors · doi:10.3390/s21175857 · Cited by 51
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 51
Zhao, D., Chen, X., Wang, L., Zhang, J., Zhao, Z., Yue, N., Zhu, Y., Fei, W., Li, X., Tan, L., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123635 · Cited by 49
Hellgren, F., Cagigi, A., Cerveira, R. A., Ols, S., Kern, T., Lin, A., Eriksson, B., Dodds, M., Jasny, E., Schwendt, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39421-5 · Cited by 49
Self-citationAn Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Blakney, A. K., Deletic, P., McKay, P. F., Bouton, C. R., Ashford, M., Shattock, R. J., & Sabirsh, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.033 · Cited by 48
Roozen, G. V. T., Prins, M., van Binnendijk, R. S., den Hartog, G., Kuiper, V. P., Prins, C., Janse, J. J., Kruithof, A. C., Feltkamp, M. C. W., Kuijer, M., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-2089 · Cited by 48
Baharom, F., Hermans, D., Delamarre, L., & Seder, R. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01091-9 · Cited by 47
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
Cai, X., Li, J. J., Liu, T., Brian, O., & Li, J. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab027 · Cited by 47
Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action
Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 46
Abdelaziz, K., Helmy, Y. A., Yitbarek, A., Hodgins, D. C., Sharafeldin, T. A., & Selim, M. H. (2024) · Vaccines · doi:10.3390/vaccines12020134 · Cited by 47
Shirai, S., Kawai, A., Shibuya, M., Munakata, L., Omata, D., Suzuki, R., & Yoshioka, Y. (2020) · Vaccines · doi:10.3390/vaccines8030433 · Cited by 44
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses
Castaño, D., Bettini, E., Kumar, B., Chudnovskiy, A., Siv, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Luna, N. D., Chiu, J. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.023 · Cited by 44
Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus
Shirai, S., Shibuya, M., Kawai, A., Tamiya, S., Munakata, L., Omata, D., Suzuki, R., Aoshi, T., & Yoshioka, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03018 · Cited by 45
Syenina, A., Gan, E. S., Toh, J. Z. N., de Alwis, R., Lin, L. Z., Tham, C. Y. L., Yee, J. X., Leong, Y. S., Sam, H., Cheong, C., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001643 · Cited by 43
Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting
Jeger‐Madiot, R., Planas, D., Staropoli, I., Debarnot, H., Kervevan, J., Mary, H., Collina, C., Fonseca, B. F., Robinot, R., Gellenoncourt, S., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240289 · Cited by 43
Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside
Ding, S., Alexander, E., Liang, H., Kulchar, R. J., SINGH, R. K., Herzog, R. W., Daniell, H., & Leong, K. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00482 · Cited by 43
Lin, A., Liang, F., Thompson, E. A., Vono, M., Ols, S., Lindgren, G., Hassett, K. J., Salter, H., Ciaramella, G., & Loré, K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701005 · Cited by 41
Self-citationHermosilla, J., Alonso-García, A., Salmerón‐García, A., Barrera, J. C., Medina-Castillo, A. L., Pérez-Robles, R., & Navas, N. (2023) · Vaccines · doi:10.3390/vaccines11111635 · Cited by 40
Maturation of germinal center B cells after influenza virus vaccination in humans
McIntire, K. M., Meng, H., Lin, T.-H., Kim, W., Moore, N. E., Han, J., McMahon, M., Wang, M., Malladi, S. K., Mohammed, B. M., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240668 · Cited by 41
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
Lenart, K., Hellgren, F., Ols, S., Yan, X., Cagigi, A., Cerveira, R. A., Winge, I. P., Hanczak, J., Mueller, S. O., Jasny, E., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.001 · Cited by 40
Self-citationRcheulishvili, N., Mao, J., Papukashvili, D., Liu, C., Wang, Z., Zhao, J., Xie, F., Pan, X., Ji, Y., He, Y., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.066 · Cited by 41
Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines
Krawczyk, P. S., Mazur, M., Orzeł, W., Gewartowska, O., Jeleń, S., Antczak, W., Kasztelan, K., Brouze, A., Matylla-Kulińska, K., Gumińska, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08842-1 · Cited by 40
Huang, L., Zhao, T., Zhao, W., Shao, A., Zhao, H., Ma, W., Gong, Y., Zeng, X., Weng, C., Bu, L., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2309985 · Cited by 37
Self-citationKorzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023) · Pharmaceuticals · doi:10.3390/ph16081088 · Cited by 40
Lukeman, H., Al-Wassiti, H. A., Fabb, S. A., Lim, L., Wang, T., Britton, W. J., Steain, M. C., Pouton, C. W., Triccas, J. A., & Counoupas, C. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105599 · Cited by 38
Blakney, A. K., Abdouni, Y., Yilmaz, G., Liu, R., McKay, P. F., Bouton, C. R., Shattock, R. J., & Becer, C. R. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00445 · Cited by 36
Designing the Next Generation of Vaccines: Relevance for Future Pandemics
Domínguez‐Andrés, J., van Crevel, R., Divangahi, M., & Netea, M. G. (2020) · mBio · doi:10.1128/mbio.02616-20 · Cited by 37
Attia, M., Essa, E. A., Elebyary, T. T., Faheem, A., & Elkordy, A. (2021) · Pharmaceuticals · doi:10.3390/ph14111173 · Cited by 36
Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines
Bolhassani, A. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00624-8 · Cited by 36
Meany, E. L., Klich, J. H., Jons, C. K., Mao, T., Chaudhary, N., Utz, A., Baillet, J., Song, Y. E., Saouaf, O. M., Ou, B. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2631 · Cited by 37
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
You, H., Jones, M. K., Gordon, C. A., Arganda, A. E., Cai, P., Al-Wassiti, H., Pouton, C. W., & McManus, D. P. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00241-21 · Cited by 39
Hengelbrock, A., Schmidt, A., & Strube, J. (2023) · Processes · doi:10.3390/pr11061718 · Cited by 33
Maltseva, M., Keeshan, A., Cooper, C., & Langlois, M. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2384192 · Cited by 34
Manners, C., Bautista, E. L., Sidoti, H., & López, O. J. (2020) · Cureus · doi:10.7759/cureus.8399 · Cited by 33
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 35
Hellgren, F., Rosdahl, A., Cerveira, R. A., Lenart, K., Ols, S., Gwon, Y.-D., Kurt, S., Delis, A. M., Joas, G., Evander, M., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175401 · Cited by 32
Self-citationmRNA-Based Vaccines and Mode of Action
Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 36
mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship
Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 33
Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles
Kim, H., Kirtane, A. R., Kim, N. Y., Rajesh, N. U., Tang, C., Ishida, K., Hayward, A. M., Langer, R., & Traverso, G. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00844-z · Cited by 31
Animal Models Utilized for the Development of Influenza Virus Vaccines
Roubidoux, E. K., & Schultz‐Cherry, S. (2021) · Vaccines · doi:10.3390/vaccines9070787 · Cited by 31
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32
Kurteva, E., Vasilev, G., Tumangelova-Yuzeir, K., Ivanova, I., Ivanova‐Todorova, E., Velikova, T., & Kyurkchiev, D. (2022) · Rheumatology International · doi:10.1007/s00296-022-05091-7 · Cited by 33
Ohno, H., Akamine, S., Mochizuki, M., Hayashi, K., Akichika, S., Suzuki, T., & Saito, H. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad019 · Cited by 31
Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development
He, Z., Li, F., Liu, M., Liao, J., & Guo, C. (2025) · Vaccines · doi:10.3390/vaccines13030260 · Cited by 29
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
Bell, M. R., & Kutzler, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114175 · Cited by 29
Have mRNA vaccines sentenced DNA vaccines to death?
Cagigi, A., & Douradinha, B. G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2282065 · Cited by 30
Lipid-based nanoparticles for cancer immunotherapy
Fan, S., Han, H., Yan, Z., Lu, Y., He, B., & Zhang, Q. (2023) · Medical Review · doi:10.1515/mr-2023-0020 · Cited by 30
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations
Omidi, Y., Pourseif, M. M., Ansari, R. A., & Barar, J. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2419815 · Cited by 29
Sato, Y. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00705 · Cited by 29
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
Wang, Z., Jacobus, E. J., Stirling, D. C., Krumm, S. A., Flight, K. E., Cunliffe, R. F., Mottl, J., Singh, C., Mosscrop, L. G., Santiago, L. A., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102045 · Cited by 30
Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies
Zoroddu, S., & Bagella, L. (2025) · Cells · doi:10.3390/cells14181476 · Cited by 28
Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation
Rouilleault, A. C. I., Soriano, I., Quan, P. L., Fernández‐Montero, A., Elizalde, A., & Pina, L. (2021) · European Radiology · doi:10.1007/s00330-021-08309-7 · Cited by 26
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions
Hsiung, K. C., Chiang, H.-J., Reinig, S., & Shih, S. (2024) · Vaccines · doi:10.3390/vaccines12121345 · Cited by 25
Fournier, C., Mercey-Ressejac, M., Dérangère, V., Kadi, A. A., Rageot, D., Charrat, C., Leroy, A., Vollaire, J., Josserand, V., Escudé, M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2024.105543 · Cited by 27
Monitoring mRNA vaccine antigen expression in vivo using PET/CT
Blizard, G. S., Dwivedi, G., Pan, Y., Hou, C., Etersque, J. M., Said, H., Chevrier, A., Lavertu, M., Ni, H., Davis, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57446-w · Cited by 25
Ziegler, L., Klemis, V., Schmidt, T., Schneitler, S., Baum, C., Neumann, J., Becker, S. L., Gärtner, B. C., Sester, U., & Sester, M. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104743 · Cited by 25
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
Walle, T., Bajaj, S., Kraske, J. A., Rösner, T., Cussigh, C. S., Kälber, K. A., Müller, L. J., Strobel, S. B., Burghaus, J., Kallenberger, S. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00398-7 · Cited by 24
Ji, A., Xu, M., Pan, Y., Diao, L., Ma, L., Li, Q., Cheng, J., & Liu, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03445-1 · Cited by 24
Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine
Abdellatif, A. A. H., Younis, M. A., Alsowinea, A. F., Abdallah, E. M., Abdel‐Bakky, M. S., Al-Subaiyel, A., Hassan, Y. A., & Tawfeek, H. M. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113111 · Cited by 24
The race toward a universal influenza vaccine: Front runners and the future directions
Hu, L., Lao, G., Liu, R., Feng, J., Long, F., & Peng, T. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105505 · Cited by 26
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging
Lemdani, K., Marlin, R., Mayet, C., Perkov, V., Pascal, Q., Ripoll, M., Relouzat, F., Dhooge, N., Bossevot, L., Dereuddre‐Bosquet, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00900-5 · Cited by 25
Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response
Dowell, W. R., Dearborn, J. S., Languon, S., Miller, Z. D., Kirch, T., Paige, S., Garvin, O., Kjendal, L., Harby, E., Zuchowski, A. B., et al. (2024) · The Journal of Immunology · doi:10.1021/acsnano.4c08490 · Cited by 23
Bar‐On, L., Cohen, H., Elia, U., Cherry, L., Cohen, O., & Noam Erez, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1670350 · Cited by 25
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.16197 · Cited by 23
Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines
Matsumura, T., Takano, T., & Takahashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac064 · Cited by 21
Mooij, P., Grødeland, G., Koopman, G., Andersen, T. K., Mortier, D., Nieuwenhuis, I. G., Verschoor, E. J., Fagrouch, Z. C., Bogers, W. M. J. M., & Bogen, B. (2019) · Vaccine · doi:10.1016/j.vaccine.2018.12.049 · Cited by 22
Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine
Komori, M., Morey, A. L., Quiñones-Molina, A. A., Fofana, J., Romero, L., Peters, E., Matsuda, K., Gummuluru, S., Smith, J. F., Akahata, W., et al. (2023) · doi:10.1101/2023.11.01.565056 · Cited by 21
Dai, W., Xing, M., Sun, L., Lv, L., Wang, X., Wang, Y., Pang, X., Guo, Y., Ren, J., & Zhou, D. (2024) · Journal of Virology · doi:10.1128/jvi.01699-24 · Cited by 22
Progress in cancer vaccines enabled by nanotechnology
Kim, B., Abdelfattah, N. S., Hostetler, A., & Irvine, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02021-z · Cited by 22
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization
Selvaggio, G., Leonardelli, L., Lofano, G., Fresnay, S., Parolo, S., Medini, D., Siena, E., & Marchetti, L. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12721 · Cited by 21
Ackun‐Farmmer, M. A., & Jewell, C. M. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200135 · Cited by 21
Sonoda, J., Mizoguchi, I., Inoué, S., Watanabe, A., Sekine, A., Yamagishi, M., Miyakawa, S., Yamaguchi, N., Horio, E., Katahira, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109094 · Cited by 23
Suzuki, Y., Katsurada, Y., & Hyodo, K. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00547 · Cited by 23
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 22
DNA vaccines as promising immuno-therapeutics against cancer: a new insight
Shariati, A., Khezrpour, A., Shariati, F. S., Afkhami, H., Yarahmadi, A., Alavimanesh, S., Kamrani, S., Modarressi, M. H., & Khani, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498431 · Cited by 21
Universal influenza virus vaccines: what needs to happen next?
Trucchi, C., Paganino, C., Amicizia, D., Orsi, A., Tisa, V., Piazza, M. F., Icardi, G., & Ansaldi, F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1604671 · Cited by 21
Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
Bartley, J. M., Cadar, A. N., & Martin, D. E. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1909617 · Cited by 21
The trillion dollar vaccine gap
Pecetta, S., Tortorice, D. L., Scorza, F. B., Pizza, M., Dougan, G., Hatchett, R. J., BLACK, S. B., Bloom, D. E., & Rappuoli, R. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn4342 · Cited by 20
A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
Dogra, P., Schiavone, C., Wang, Z., Ruiz-Ramírez, J., Caserta, S., Staquicini, D. I., Markosian, C., Wang, J., Sostman, D. H., Pasqualini, R., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.169860 · Cited by 21
Granot-Matok, Y., Ezra, A., Ramishetti, S., Sharma, P., Naidu, G. S., Benhar, I., & Peer, D. (2023) · Theranostics · doi:10.7150/thno.82228 · Cited by 20
Metadata
- Authors
- Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., Brito, L. A., Salter, H., Ciaramella, G., & Loré, K.
- Affiliations
- Karolinska Institutet (SE)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Loré, Karin
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 25
- Issue
- 12
- Pages
- 2635-2647
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC5768558
- OpenAlex
- W2745973480
- Cited by
- 395
- References
- 50
- Citations by year
- 2026: 33 · 2025: 69 · 2024: 60 · 2023: 53 · 2022: 66 · 2021: 62 · 2020: 23 · 2019: 20 · 2018: 7 · 2017: 2
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Swedish Research Council (2015-02608)
- Fernström Foundation
- Swedish Society of Medicine
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Keywords
- mRNA vaccines, lipid nanoparticles, antigen-presenting cells, dendritic cells, monocytes, CD4+ T cell responses, type I interferon, MX1, CXCL10, intradermal vaccination, intramuscular vaccination, innate immune activation, rhesus monkeys
- MeSH terms
- Animals, Antigen-Presenting Cells, Immunization, Influenza Vaccines, Injections, Intradermal, Lymph Nodes, Macaca mulatta, Phenotype, RNA, Messenger, T-Lymphocytes, Vaccines, Gene Expression, Immunophenotyping, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
